Business Context and Reporting Period
Company: Aastrom Biosciences, Inc. (Note: Request metadata listed "Vericel Corp," but the filing text identifies the registrant as Aastrom Biosciences, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: June 30, 2001
Business Overview: Aastrom is a development-stage biotechnology company focused on the ex vivo production of human cells for cell therapy and gene therapy. Its lead product, the AastromReplicell System, is designed to automate the production of stem cells, dendritic cells, and other therapeutic cells. The company has received CE Mark approval for certain stem cell therapy products in Europe but is still seeking FDA approval for U.S. commercialization.
Key Financial Metrics
| Metric | Year Ended June 30, 2001 | Year Ended June 30, 2000 |
|---|---|---|
| Total Revenues | $899,000 | $1,150,000 |
| Net Loss | $(5,926,000) | $(9,390,000) |
| Net Loss Per Share (Basic & Diluted) | $(0.17) | $(0.41) |
| Cash, Cash Equivalents & Short-Term Investments | $10,659,000 | $12,745,000 |
| Working Capital | $10,715,000 | $12,143,000 |
| Total Assets | $11,905,000 | $13,437,000 |
| Accumulated Deficit | $(85,858,000) | $(79,932,000) |
Revenue Composition (2001): Grant revenues accounted for $814,000 (91% of total), while product sales and rentals were $85,000. Research and development agreements contributed $0 in 2001.
Expenses (2001): Total costs and expenses were $7,478,000, driven primarily by Research and Development ($4,983,000) and Selling, General, and Administrative expenses ($2,482,000).
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased 22% from $1.15 million in 2000 to $899,000 in 2001. This was primarily due to a decrease in grant revenues ($981,000 to $814,000) and a drop in product sales ($169,000 to $85,000).
- Reduced Net Loss: The net loss improved significantly, decreasing by 37% from $9.39 million in 2000 to $5.93 million in 2001. This improvement was driven by a reduction in R&D expenses ($6.29M to $4.98M) and SG&A expenses ($3.36M to $2.48M) following cost-reduction measures implemented in late 1999.
- Inventory Write-off (2000 Context): The 2000 financials included a $1.027 million inventory write-off related to the suspension of European marketing activities. No such write-off occurred in 2001.
- Cash Position: Cash and short-term investments decreased by approximately $2.1 million year-over-year, despite raising $4.265 million in net proceeds from equity sales during the year. The decrease was due to operating cash usage of $6.36 million.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Guidance:
- The company expects to continue incurring net operating losses until significant product sales commence, which is unlikely until additional funding is secured and regulatory approvals are obtained.
- Management estimates that current cash reserves and expected interest income are sufficient to finance planned activities through at least the end of fiscal year 2002.
- Future operations depend on raising additional capital through public/private equity sales, grants, or collaborative agreements.
Key Risks and Contingencies:
- Regulatory Approval: U.S. commercialization requires FDA approval (likely as a Class III medical device or biologic), which is uncertain and costly. European marketing relies on CE Mark status, which could change.
- Liquidity: The company has never been profitable and has an accumulated deficit of $85.9 million. Failure to secure additional funding could force substantial reductions in operations.
- Third-Party Dependence: Manufacturing relies entirely on third-party suppliers (e.g., SeaMED for instruments, Immunex for cytokines). Supply interruptions could halt clinical trials.
- Competition: The stem cell therapy market is dominated by established bone marrow harvest and PBSC collection methods. Aastrom must prove its technology is competitive in cost and efficacy.
Unusual Items:
- Executive Departure: Todd E. Simpson, Vice President of Finance and CFO, resigned to pursue other opportunities. The company is in the process of hiring a replacement.
- Subsequent Event: Between July 1, 2001, and August 31, 2001, the company issued 4,345,182 shares of common stock for approximately $6.5 million in cash proceeds.
Investor Verification Checklist
- Cash Runway: Verify if the company has secured the additional funding required to extend operations beyond the projected end of fiscal year 2002.
- Regulatory Status: Confirm the current status of FDA Investigational Device Exemptions (IDEs) and any updates on the Pre-Market Approval (PMA) pathway for the AastromReplicell System.
- European Sales: Assess the actual volume of product sales in Europe following the resumption of marketing activities and the impact of the CE Mark on revenue growth.
- Supply Chain Stability: Review the status of agreements with key suppliers (SeaMED, Immunex, Anchor Advanced Products) to ensure no disruptions in component supply.
- Management Continuity: Monitor the appointment of a permanent Chief Financial Officer following the departure of Todd E. Simpson.